enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Genentech - Wikipedia

    en.wikipedia.org/wiki/Genentech

    Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]

  3. Timeline of biotechnology - Wikipedia

    en.wikipedia.org/wiki/Timeline_of_biotechnology

    1982 – Humulin, Genentech's human insulin drug produced by genetically engineered bacteria for the treatment of diabetes, is the first biotech drug to be approved by the Food and Drug Administration. 1983 – The Polymerase Chain Reaction (PCR) technique is conceived.

  4. Insulin (medication) - Wikipedia

    en.wikipedia.org/wiki/Insulin_(medication)

    Genentech developed the technique used to produce the first such insulin, Humulin, but did not commercially market the product themselves. Eli Lilly marketed Humulin in 1982. [28] Humulin was the first medication produced using modern genetic engineering techniques in which actual human DNA is inserted into a host cell (E. coli in this case ...

  5. FDA Approves Genentech's Kadcyla (Ado-Trastuzumab ... - AOL

    www.aol.com/news/2013-02-22-fda-approves...

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...

  6. Trastuzumab emtansine - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_emtansine

    Trastuzumab is the anti-HER2 antibody; emtansine refers to the linker-drug (SMCC-DM1). The "ado-" prefix was added at the request of the FDA to help prevent dispensing errors . [ 31 ] [ 20 ] [ 32 ] During preclinical development and clinical trials, the drug was also known as trastuzumab-DM1 or trastuzumab-MCC-DM1 (after the codename for ...

  7. FDA Files Genentech's Supplemental Biologics License ...

    www.aol.com/news/2013-10-11-fda-files-genentechs...

    FDA Files Genentech's Supplemental Biologics License Application of Xolair ® (omalizumab) for Chronic Idiopathic Urticaria (CIU) CIU is a skin condition characterized by red, swollen, itchy hives ...

  8. Genentech to Present Important New Data Reflecting Broad ...

    www.aol.com/news/2013-05-15-genentech-to-present...

    Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers --

  9. Herbert Boyer - Wikipedia

    en.wikipedia.org/wiki/Herbert_Boyer

    Herbert Wayne "Herb" Boyer (born July 10, 1936) is an American biotechnologist, researcher and entrepreneur in biotechnology. Along with Stanley N. Cohen and Paul Berg, he discovered recombinant DNA, a method to coax bacteria into producing foreign proteins, which aided in jump-starting the field of genetic engineering.